Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
04:21pm, Thursday, 05'th Mar 2026
Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS)
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
08:00am, Tuesday, 03'rd Mar 2026
EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune dise
Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution
01:02am, Tuesday, 03'rd Mar 2026
Kyverna Therapeutics leads CAR-T therapy for autoimmune diseases, with KYV-101 showing unprecedented efficacy in SPS and MG registrational trials. KYTX's SPS trial achieved 81% clinically meaningful i
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
08:00am, Tuesday, 24'th Feb 2026
Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
09:40am, Monday, 16'th Feb 2026
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
08:00am, Tuesday, 03'rd Feb 2026
EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune disea
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
08:00am, Monday, 12'th Jan 2026
Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient e
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
08:00am, Monday, 05'th Jan 2026
EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients w
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
09:01am, Tuesday, 30'th Dec 2025
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies
02:48pm, Thursday, 18'th Dec 2025
Kyverna Therapeutics is upgraded to 'Buy' based on strengthened financials and the potential for commercial launch by the end of 2026. Phase 2 data for mivocabtagene autoleucel shows strong efficacy a
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
11:59am, Wednesday, 17'th Dec 2025
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
09:24am, Wednesday, 17'th Dec 2025
EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for pat
Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing
03:46pm, Tuesday, 16'th Dec 2025
Kyverna Therapeutics (KYTX) is upgraded to "Strong Buy" following positive phase 2 data for miv-cel in SPS and MG indications. Company achieved a 46% average improvement in SPS patients in phase 2 KYS
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
11:11am, Tuesday, 16'th Dec 2025
Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
10:26am, Tuesday, 16'th Dec 2025
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements wit
